BCL2L1 and meningioma: Everolimus and gemcitabine-treated malignant meningioma cells were sensitive to A-1331852 and A-1155463, but less sensitive to venetoclax, suggesting increased dependency on BCL-xL rather than BCL-2 (Figure S3b).